Trial Profile
A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Patients With Stable Atherothrombotic Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs CSL 112 (Primary)
- Indications Atherosclerosis
- Focus Adverse reactions
- Sponsors CSL; CSL Behring
- 04 Apr 2022 Data from 5 clinical trials (single and multiple ascending dose phase 1 studies in healthy volunteers, a phase 2a study in subjects with stable atherosclerotic disease, a phase 2b study in subjects post-AMI (AEGIS-I), and a phase 1 Japanese ethno-bridging study) assessing pharmacokinetics (PK) and pharmacodynamics (PD) of CSL112 across different populations, presented at the 71st Annual Scientific Session of the American College of Cardiology.
- 20 Nov 2013 Results assessing potential antiplatelet effects of CSL 112 presented at the 86th Annual Scientific Sessions of the American Heart Association.
- 19 Nov 2013 Biomarker results presented at the 86th Annual Scientific Sessions of the American Heart Association.